钙拮抗剂治疗高血压重要临床试验回顾.pptxVIP

钙拮抗剂治疗高血压重要临床试验回顾;钙拮抗剂治疗高血压重要临床试验回顾;高血压治疗研究进程;有关钙拮抗剂的重要临床试验;达到终点的患者比例％;INSIGHT试验;NORDIL(the Nordic Diltiazem Study);NICS-EH;因心脑血管合并症出现终止两组累积进行率;PATE-H Study;PATE-H 一级终点事件 (每1000病人年);老年人高血压临床试验终点事件数比较 (/1000病人年);WHO/ISH Blood Pressure Lowering Trialists’ Collaboration (BPLT临床试验协作研究);BPLT协作研究的背景;BPLT协作研究入选临床试验标准;入选的临床试验(一);入选的临床试验(二);入选的临床试验(三);BPLT协作研究一级终点;By 2003, the available data should provide good power to detect modest differences in the incidence of each of the principal outcomes for the main treatment comparisons. By 1999, however, the power to assess such cause- specific treatment effects is likely to be suboptimal, so the principal focus of analyses at that time will be the combined outcome of total cardiovascular events.;BPLT协作研究第一轮分析入选的临床试验;相对危险计算;BPLT协作研究第一轮分析结果(一) ; ACEI Placebo Relative risk(95% CI) Major cardiovascular events HOPE 726/4645 919/4652 0.79(0.72-0.86) PART2 33/308 40/309 0.83(0.54-1.28) QUIET 49/878 55/872 0.88(0.61-1.29) SCAT 12/229 26/231 0.47(0.24-0.90) Overall 820/6060 1040/6064 0.79(0.73-0.86) (p homog=0.81) Cardiovascular death HOPE 282/4645 377/4652 0.75(0.72-0.91) PART2 8/308 18/309 0.45(0.20-1.01) QUIET 13/878 14/872 0.92(0.44-1.95) SCAT 4/229 7/231 0.58(0.17-1.94) Overall 307/6060 416/6064 0.74(0.7264-0.85) (p homog=0.57) Total mortality HOPE 482/4645 569/4652 0.85(0.76-0.95) PART2 16/308 25/309 0.64(0.35-1.18) QUIET 27/878 27/872 0.99(0.59-1.68) SCAT 8/229 11/231 0.73(0.30-1.79) Overall 533/6060 632/6064 0.84(0.76-0.94) (p homog=0.74); Calcium Placebo Relative risk antagonistsI (95% CI) Major cardiovascular events PREVENT 24/417 30/408 0.78(0.47-1.32) SYST-EUR 142/2398 192/2297 0.71(0.57-0.87) Overall 166/2815 222/2705 0.72(0.59-0.87) (p homog=0.73) Cardiovascular death PREVENT 2/417 7/408 0.28(0.06-1.34) SYST-EUR 64/2398 82/2297 0.75(0.54-1.03) Overall 66/2815 89/2705 0.72(0.52-0.98) (p homog=0.23) Total mortallty PREVENT 6/417 8/408 0.73(0.26-2.10) SYST-EUR 135/2398 147/2297 0.88(0.70-1.10) Overall 141/2815 155/2